Frontiers in Pharmacology | Pharmacoepidemiology

Brief Research Report

Published on 03 Nov 2023

Statutory health insurance-covered pre-exposure prophylaxis in Germany: changing trends in nationwide tenofovir disoproxil/emtricitabine prescriptions during the COVID-19 pandemic

in Pharmacoepidemiology

Henrieke Prins
Achim Dörre
Daniel Schmidt

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1241310

3,789 views
1 citation

Original Research

Published on 01 Nov 2023

Associations between COVID-19 outcomes and asthmatic patients with inhaled corticosteroid

in Pharmacoepidemiology

Su-Boon Yong
Shuo-Yan Gau
Chia-Jung Li
Chih-Wei Tseng
Shiow-Ing Wang
James Cheng-Chung Wei

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1204297

2,703 views
10 citations

Original Research

Published on 31 Oct 2023

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system

in Pharmacoepidemiology

Yankun Liang
Lin Ma
Yuting Wang
Jingping Zheng
Ling Su
Jun Lyu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1253799

4,334 views
4 citations

Original Research

Published on 30 Oct 2023

Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study

in Pharmacoepidemiology

Yun-Kyoung Song
Gaeun Lee
Jinseub Hwang
Ji-Won Kim
Jin-Won Kwon

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1165711

4,272 views
5 citations

Original Research

Published on 30 Oct 2023

Do disease-modifying antirheumatic drugs and non-steroidal anti-inflammatory drugs increase the burden on ankylosing spondylitis patients with mild-moderate COVID-19? evidence from a retrospective cohort study

in Pharmacoepidemiology

Yan Li
Zhengyuan Hu
Yufei Guo
Zheng Zhao
Kunpeng Li
Xiuru Wang
Jie Zhang
Dongfeng Liang
Jianglin Zhang
Xiaoyue Hu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1266915

1,717 views
3 citations

Original Research

Published on 26 Oct 2023

Big data- and machine learning-based analysis of a global pharmacovigilance database enables the discovery of sex-specific differences in the safety profile of dual IL4/IL13 blockade

in Pharmacoepidemiology

Kassem Sharif
Mahmud Omar
Adi Lahat
Yonatan Shneor Patt
Howard Amital
Ghanem Zoabi
Nicola Luigi Bragazzi
Abdulla Watad

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1271309

2,837 views
2 citations

Original Research

Published on 26 Oct 2023

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?

in Pharmacoepidemiology

Zhiwei Cui
Feiyan Cheng
Lihui Wang
Fan Zou
Rumeng Pan
Yuhan Tian
Xiyuan Zhang
Jing She
Yidan Zhang
Xinyuan Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1259908

5,358 views
15 citations

Systematic Review

Published on 24 Oct 2023

Comparison of biologics and small-molecule drugs in axial spondyloarthritis: a systematic review and network meta-analysis

in Pharmacoepidemiology

Erye Zhou
Jian Wu
Keqin Zeng
Mingjun Wang
Yufeng Yin

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1226528

3,769 views
5 citations

Original Research

Published on 20 Oct 2023

Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization’s database

in Pharmacoepidemiology

Rachel Prevost
Basile Chretien
Elise-Marie Minoc
Charles Dolladille
Angélique Da-Silva
Ahmad Nehme
Florence Joly
Véronique Lelong-Boulouard
Etienne Bastien

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1278682

3,407 views
3 citations

Opinion

Published on 11 Oct 2023

Nutrivigilance: the road less traveled

in Pharmacoepidemiology

Vijay Ronit Luthra
Hale Z. Toklu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1274810

4,071 views
3 citations

Policy and Practice Reviews

Published on 11 Oct 2023

A blueprint for success in real-world evidence: “glocal” approach to building capabilities and generating impactful evidence

in Pharmacoepidemiology

Kristoffer Larsen
Ryan N. Walton
Mohamed Elsayed
Andrey Ipatov
Faye Townsend-Holyoake
Sebastian F. A. Axelsson
Nacho Quinones
Rudiger Papsch
Jennifer Givens
Alexander Bedenkov

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1233617

7,344 views

Brief Research Report

Published on 10 Oct 2023

A retrospective real-world study of early short-course remdesivir in non-hospitalized COVID-19 patients at high risk for progression: low rate of hospitalization or death, regardless of immunocompetence status

in Pharmacoepidemiology

José Manuel Ramos-Rincón
Héctor Pinargote-Celorio
Jara Llenas-García
Oscar Moreno-Pérez
Inmaculada González-Cuello
Pilar Gonzalez-de-la-Aleja
Belén Martínez-López
Sergio Reus
María García-López
Juan Carlos Rodríguez

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1218650

2,334 views
5 citations

Original Research

Published on 09 Oct 2023

Impact of domiciliary administration of NSAIDs on COVID-19 hospital outcomes: an unCoVer analysis

in Pharmacoepidemiology

Elena Salvador
Cristina Mazzi
Nicoletta De Santis
Giulia Bertoli
Antonija Jonjić
Miran Coklo
Marek Majdan
José L. Peñalvo
Dora Buonfrate

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1252800

1,269 views

Original Research

Published on 02 Oct 2023

Infections associated with clozapine: a pharmacovigilance study using VigiBase®

in Pharmacoepidemiology

Basile Chrétien
Perrine Brazo
Angélique Da Silva
Marion Sassier
Charles Dolladille
Véronique Lelong-Boulouard
Joachim Alexandre
Sophie Fedrizzi

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1260915

3,736 views
4 citations

Original Research

Published on 28 Sep 2023

Impact of implementing a vancomycin protocol to reduce kidney toxicity: A comparative study

in Pharmacoepidemiology

Graziella Gasparotto Baiocco
Stephanie Greiner
Mário Borges Rosa
Cecília Dias Flores
Helena M. T. Barros

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1154573

2,444 views

Original Research

Published on 25 Sep 2023

Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy

in Pharmacoepidemiology

Irma Convertino
Massimiliano Cazzato
Silvia Tillati
Sabrina Giometto
Rosa Gini
Giulia Valdiserra
Emiliano Cappello
Sara Ferraro
Marco Bonaso
Claudia Bartolini

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1244486

1,914 views